Key facts
- This page summarizes ARMISTICE CAPITAL, LLC's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jun 2023, 18:12.
ARMISTICE CAPITAL, LLC - 26 Jun 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AVTX
- Reported as of
- 26 Jun 2023
- Net transaction value
- -$2,168,897
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2023, 18:12:57 UTC
- Prior SEC filing
- 09 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- ARMISTICE CAPITAL, LLC, Name: /s/ Steven Boyd, Title: Managing Member
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
ARMISTICE CAPITAL, LLC filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 28 Jun 2023.
Change
- Previous filing in this sequence was filed on 09 Feb 2023.
- Current net transaction value: -$2,168,897.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTX
transaction
Common Stock
Sale
- Transaction value
- $1,682,010
- Shares
- -2,746,138
- Change %
- -62%
- Price
- $0.6125
- Shares after
- 1,668,862
- Date
- 26 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2
AVTX
transaction
Common Stock
Sale
- Transaction value
- $486,888
- Shares
- -937,404
- Change %
- -56%
- Price
- $0.5194
- Shares after
- 731,458
- Date
- 27 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F2, F3
AVTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 34,370
- Date
- 26 Jun 2023
- Ownership
- Direct
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.50 to $0.7801, inclusive. The Reporting Person undertakes to provide to Avalo Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and footnote 3.
Footnote F2
The reported securities of the Issuer are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4976 to $0.5985, inclusive.
Footnote F4
These shares are directly owned by Mr. Boyd in his personal capacity.